Investment case
Moderna, Inc.
MRNA · 41 developments mapped · last assessed 2026-09-29
Market Ontology has mapped 41 macro, policy, and market developments to Moderna, Inc. since 2026-08-12. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for MRNA yet, so no modelled value is shown. The MRNA valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run MRNA on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Moderna and Merck Report Positive Phase III Trial Results for mRNA Cancer Therapy
Direct commercialization opportunity for a novel oncology therapy, expanding addressable market beyond infectious diseases.
· Moves peak sales estimates for oncology pipeline, probability of success for mrna oncology platform, discount rate reflecting reduced clinical risk
- Open question
Pfizer and Nvidia Back $80M AI Computational Immunology Venture
Increased competitive pressure in vaccine development and AI-driven drug discovery from established players leveraging advanced computational methods.
· Moves competitive landscape, r&d efficiency relative to peers
What changed, by assumption
- 2026-09-16Moderna and Merck Report Positive Phase III Trial Results for mRNA Cancer Therapy
- 2026-09-17Over 40 Late-Stage Hypertension Trials Progress Across RNAi and Novel Pathways
- 2026-09-25Pfizer and NVIDIA Form $80M CytoReason Venture as Vaccine AI R&D Expands
- 2026-09-27Hangzhou Global Open-Source AI Challenge Awards 1M RMB to Peptide Algorithm
- 2026-09-27Hangzhou Global Open-Source AI Finals Conclude with 1M RMB Biotech Prize
- 2026-09-25Pfizer and NVIDIA Form $80M Joint Venture in AI-Driven Vaccine Discovery
- 2026-09-25Pfizer and Nvidia Back $80M AI Computational Immunology Venture
- 2026-09-25Pfizer and NVIDIA Back $80M CytoReason Venture for AI Vaccine Adjuvant Discovery
- 2026-09-25Pfizer and Nvidia deploy $80M joint investment into CytoReason AI platform
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-08-29 | Share count | Bullish | Issuance of convertible senior notes typically leads to potential share count dilution upon conversion. | 0.90 |
| 2026-08-29 | Interest expense | Bullish | Coupon adds to interest expense until conversion. | 0.70 |
| 2026-08-29 | Dilution | Bullish | Convertible issuance creates contingent dilution at conversion price. | 0.70 |
| 2026-07-31 | Capital expenditure | Bearish | Company guidance for 2026 capital expenditures is $0.2 to $0.3 billion. | 0.90 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-29 | Oncolytics Biotech Inc Announces Publication of Pelareorep Liver Cancer Data | watch | 3-12m | 0.10 |
| 2026-09-29 | Invivyd Announces Regulatory Submission Plans for VYD2311 via Accelerated Approval Program | watch | 3-12m | 0.20 |
| 2026-09-29 | Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million | watch | 3-12m | 0.30 |
| 2026-09-29 | Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Priority Review Voucher | watch | 3-12m | 0.30 |
| 2026-09-27 | Hangzhou Global Open-Source AI Challenge Awards 1M RMB to Peptide Algorithm | Bullish | 3-12m | 0.30 |
| 2026-09-27 | Hangzhou Global Open-Source AI Finals Conclude with 1M RMB Biotech Prize | Bullish | 1-5y | 0.30 |
| 2026-09-25 | Moleculin Biotech, Inc. Announces New Preclinical Data for Annamycin in Pancreatic Cancer at AACR | watch | 3-12m | 0.20 |
| 2026-09-25 | Pfizer and NVIDIA Form $80M Joint Venture in AI Biopharma Platform CytoReason | mixed | 3-12m | 0.30 |
| 2026-09-25 | Pfizer and Nvidia Back $80M AI Computational Immunology Venture | watch | 1-3m | 0.40 |
| 2026-09-25 | Pfizer and Nvidia deploy $80M joint investment into CytoReason AI platform | mixed | 1-5y | 0.40 |
| 2026-09-25 | ADARx Pharma Prices Upsized $446.3M IPO at $17 on Nasdaq | Bullish | 1-3m | 0.20 |
| 2026-09-25 | Pfizer and Nvidia Form $80M CytoReason AI Drug Discovery JV | watch | 3-12m | 0.40 |